http://web.archive.org/web/20140225133910id_/http://www.dailymail.co.uk/news/article-2567332/Skin-cancer-wonder-drug-increase-lifespan-three-years-withheld-NHS-patients-undergo-chemotherapy.html

by @entity0 published : 04:03 est , 25 february 2014 @entity2 : 07:06 est , 25 february 2014 a new ‘ wonder ’ drug which increases survival from the most dangerous form of skin cancer must be withheld until patients have undergone chemotherapy , says the @entity10 rationing watchdog			2
ipilimumab increases lifespan by an average of four months in patients with malignant melanoma where the cancer has spread to other organs			1
but trial data shows more than one in five patients lives for at least three years after treatment			0
it is estimated the drug can help between 1,000 and 2,000 patients in the @entity25 each year , many of them in their 20s and 30s			1
@entity11 , also known as @entity11 , is used to treat advanced melanoma			1
but @entity10 patients can only get access to it once they have undergone chemotherapy the @entity32 ( @entity32 ) admits the drug is ‘ life - extending ’ and has already approved its use after chemotherapy			0
but a new licence means the drug could be used earlier , before patients have to suffer debilitating side effects from chemo such as hair loss			1
however , @entity32 says ipilimumab should not be available for patients at this first line stage , only if they take part in clinical trials			0
the decision has alarmed doctors and campaigners , particularly as the @entity50 says the change would be cost neutral - adding nothing to the @entity10 bill			1
more than 10,400 people are diagnosed with malignant melanoma each year and 2,000 people die			1
it is the most common kind of cancer for women in their 20s patients in the @entity61 have been able to use the drug immediately they are diagnosed with advanced disease for the last three years because the authorities recognised the benefit			0
@entity66 , of the charity melanoma @entity25 , said : ' advanced melanoma is a devastating diagnosis , yet treatment options remain severely limited for many patients facing this disease			1
‘ unless reversed , this decision by @entity32 will sadly continue this trend and will leave some patients without a medicine that could potentially help extend their lives			0
’ around 12,800 @entity25 are diagnosed each year with melanoma , of which 2,200 die			1
manufacturer @entity78 says the therapy - which stimulates the patient ’s own immune system to fight cancer - has the potential to offer long - term survival to some			0
treatment costs around £ 63,000 , less an undisclosed discount to the @entity10			0
guidance issued by @entity32 in december 2012 , gave the go - ahead for use of the drug , also known as @entity11 , on the @entity10 for advanced malignant melanoma patients who have already undergone chemotherapy			2
at the time , @entity32 called the drug a ‘ breakthrough treatment ’ saying that it could ‘ potentially significantly improve the prognosis for some people with malignant melanoma '			2
last year , @entity102 health officials extended the licence of the drug so it could also be used in previously untreated patients - not just those who had undergone chemotherapy			2
but @entity32 says the manufacturer has not provided enough evidence to show the drug as a first - line treatment can extend the lives of patients			0
trial data shows more than one in five patients lives for at least three years after treatment with @entity11			0

ipilimumab can only be used after chemo , which has *numerous* side effects
doctors and campaigners blast decision , claiming drug is ' cost neutral '
it is used to treat melanoma , which kills 2,200 @entity25 each year

@entity2:UPDATED
@entity0:Jenny Hope
@entity11:Ipilimumab
@entity10:NHS
@entity25:Britons
@entity102:European
@entity50:Cancer Drugs Fund
@entity78:Bristol-Myers Squibb
@entity32:Nice
@entity66:Gill Nuttall
@entity61:U.S.